Get 50% OFF This Summer!

Advertisement
logo

Akums Drugs & Pharmaceuticals

AKUMS
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Akums Drugs & Pharmaceuticals Share price and Fundamental Analysis

View All Details
View All Details
Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC.
Company Incorporation2004
ChairmanNA
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
8,823.51
PE Ratio
61.74
Industry P/E
35.07
PEG Ratio
0
ROE
9.8%
ROCE
7.51%
ROA
3.62%
Total Debt (Cr)
137.18
Debt to Equity
0.19
Dividend Yield
0%
EPS
9.08
Book Value & P/B
142.04 x 3.95
Face Value
2
Outstanding Shares(Cr)
15.74
Current Ratio
3.21
EV to Sales
2.14

Included In

+More

Stock Returns

1 Week+8.35%
1 Month+11.79%
6 Months+0.9%
1 Year-29.92%
3 Years-29.92%
5 Years-29.92%

CAGR

1 Year CAGR

Revenue Growth

+14.32%

Net Profit Growth

-99.19%

Operating Profit Growth

-57.69%

Dividend Growth

N/A

Stock Returns CAGR

-29.92%
no_data

No Stocks

Smart Score

1.5
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 75.26%

FIIs : 5.77%

DIIs : 7.40%

Public : 11.58%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
DII Shareholding Increased by 0.4% to 7.4% in March 2025 Qtr
FII Shareholding Decreased by 0.59% to 5.77% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Akums Drugs & Pharmaceuticals Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Akums Drugs & Pharmaceuticals Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC.

Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients. Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services. Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation. Their specialization extends to development and sale of APIs across diverse chemical processes and therapeutic areas such as anti-infective, respiratory and diabetes.

In 2004, the Company established first plant for oral dosage commissioned at 19, 20, 21, Sector 6A, Haridwar, Uttarakhand. In 2007, it established dedicated manufacturing site for oral liquid dosage and sterile products both at Haridwar, Uttarakhand. It incorporated Maxcure Nutravedics Limited to venture into nutraceuticals in 2009. In 2010, it dedicated a facility for hormones ; dedicated a facility for cosmetics and dermatology at Haridwar, Uttarakhand. In 2010, it incorporated Akumentis Healthcare Limited to venture into branded formulations.

In 2011, it innovated bi-layered sustained release tablets for the first time. In 2012, acquired subsidiary, Pure and Cure Healthcare Private Limited to expand capacity and capabilities. In 2013, it acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities. It established R&D Laboratory in Mumbai, Maharashtra to venture into regulated market in 2015.

In 2021, the Company acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs. Further, it acquired Kotdwar Plant in Uttarakhand by Akums Healthcare Limited. In 2022, it acquired facility in Haridwar, Uttarakhand through the subsidiaries, Akums Healthcare Limited and in 2023, acquired Baddi facility in, Himachal Pradesh through Pure and Cure Healthcare Private Limited

Following a Scheme of Arrangement on October 17, 2023, Akums Lifesciences Limited got merged with its subsidiary, Pure and Cure Healthcare Private Limited (PCHL) with effect from April 1, 2022. As part of this acquisition, it acquired manufacturing units in Dera Bassi and Lalru in Punjab and Barwala in Haryana, and an R&D centre in Barwala, Haryana and commenced operations in the manufacture and sale of key starting materials, intermediates and APIs.

The Company is proposing the Public Issue by raising funds aggregating Rs 680 Crores through Fresh Issue and by issuing 18,598,365 Equity Shares through Offer for Sale.

Akums Drugs & Pharmaceuticals Share Price

Akums Drugs & Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Akums Drugs & Pharmaceuticals Market Cap

Market capitalization of Akums Drugs & Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Akums Drugs & Pharmaceuticals is valued compared to its competitors.

Akums Drugs & Pharmaceuticals PE Ratio

Akums Drugs & Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Akums Drugs & Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Akums Drugs & Pharmaceuticals PEG Ratio

The PEG ratio of Akums Drugs & Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Akums Drugs & Pharmaceuticals ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Akums Drugs & Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Akums Drugs & Pharmaceuticals ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Akums Drugs & Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Akums Drugs & Pharmaceuticals Total Debt

Total debt of Akums Drugs & Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Akums Drugs & Pharmaceuticals Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Akums Drugs & Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Akums Drugs & Pharmaceuticals CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Akums Drugs & Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Akums Drugs & Pharmaceuticals Technical Analysis

Technical analysis of Akums Drugs & Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Akums Drugs & Pharmaceuticals Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Akums Drugs & Pharmaceuticals shares often struggle to rise above due to selling pressure.

Akums Drugs & Pharmaceuticals Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Akums Drugs & Pharmaceuticals ’s financial health and profitability.

Akums Drugs & Pharmaceuticals Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Akums Drugs & Pharmaceuticals Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Akums Drugs & Pharmaceuticals Financials

The financials of Akums Drugs & Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Akums Drugs & Pharmaceuticals Profit and Loss Statements

The profit and loss statement of Akums Drugs & Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Akums Drugs & Pharmaceuticals .

Akums Drugs & Pharmaceuticals Balance Sheet

The balance sheet presents a snapshot of Akums Drugs & Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Akums Drugs & Pharmaceuticals Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App